Aptevo Therapeutics at Protein & Antibody Engineering Summit, Boston

SEATTLE, WA – Aptevo Therapeutics (NASDAQ:APVO), a biotechnology company in the clinical stage, is preparing to present at The Essential Protein & Antibody Engineering Summit (PEGS) conference in Boston, MA. Scheduled for May 14, 2024, the presentation will be conducted by Dr. Peter Pavlik, PhD, Senior Director of Protein Engineering at Aptevo. The session, titled "Development of Target Activated ADAPTIRs for Tumor Immunotherapy," is set to take place at 8:30 AM Eastern time.

Dr. Pavlik's presentation will delve into strategic methodologies for initial functional screening of various binding domains targeting specific molecules. Utilizing Aptevo’s ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, the approach involves examining multiple potential formats to achieve diverse functional activities. This strategy will be illustrated with supporting data from both preclinical and clinical studies, highlighting predictive outcomes.

"At Aptevo, our focus is on pioneering bispecific cancer therapeutics," stated Dr. Pavlik. "We are thrilled to share our insights and expertise with the PEGS conference community. Our portfolio includes two clinical candidates, APVO436 and ALG.APV-527, as well as three preclinical candidates—APVO603, APVO711, and APVO442. We have strategically engineered these candidates to ensure safety and efficacy, and our results in both clinical and laboratory settings thus far have been promising."

Aptevo continues to build a significant body of clinical evidence supporting the preclinical predictions regarding the safety, conditional activation, and clinical activity of its drug candidates. Recent updates from the company’s clinical programs include favorable developments:

A heavily pretreated breast cancer patient participating in the ALG.APV-527 Phase 1 open-label, multi-center, and multi-cohort trial for various solid tumors showed notable improvement. The patient’s condition stabilized from progressive disease to a long-lasting stable disease (SD) status while on the therapy. Remarkably, the patient has remained in the study for over eleven months and has successfully transitioned to a higher dose level without new adverse events, which could lead to increased clinical benefits. The trial is more than halfway enrolled, with dosing underway for cohort 5.

Additionally, Aptevo is on schedule to start part 1 of its dose optimization trial for APVO436 in the second quarter of 2024. This trial focuses on APVO436 as a treatment for acute myeloid leukemia (AML), in partnership with the contract research organization Prometrika. The first phase of the study will evaluate the combination of APVO436 with venetoclax and azacitidine, the current standard of care, for newly diagnosed AML patients. This open-label, multi-center, multi-cohort study aims to assess the safety, tolerability, and efficacy of the combination therapy at various dose levels.

About Dr. Pavlik
Dr. Peter Pavlik is the Senior Director of Protein Engineering at Aptevo Therapeutics. His expertise spans eight years with Aptevo, focusing on bispecific antibody development, binding domain discovery, bispecific molecule engineering, optimization of developability, and manufacturing cell line engineering. Before Aptevo, Dr. Pavlik worked for MedImmune/AstraZeneca on antibody discovery and protein engineering for eight years, and at Los Alamos National Labs for ten years on genome-scale antibody discovery technologies. He holds an M.Sc. in Biochemistry from Comenius University in Slovakia and a Ph.D. in Biochemistry from the University of Vienna in Austria.

About Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing innovative immuno-oncology therapies for cancer treatment. Focused on improving therapeutic outcomes for cancer patients, Aptevo leverages its proprietary ADAPTIR™ and ADAPTIR-FLEX™ technologies to advance its drug candidates.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!